AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Data from Theratope vaccine trial to be presented at breast cancer symposium.
2003 OCT 2 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) announced that data from the final analysis of its Theratope vaccine phase III clinical trial in metastatic breast cancer will be presented at the 26th Annual San Antonio Breast Cancer Symposium (SABCS) being held at the Henry B. Gonzalez Convention Center in San Antonio, December 3-6, 2003.
David W. Miles, MD, BSc, FRCP, senior lecturer, and honorary consultant in medical oncology at Guy's Hospital in London, England and principal clinical investigator in the trial will present the results in an oral presentation.
Theratope is an investigational therapeutic cancer vaccine designed to stimulate an immune response to the tumor associated STn marker. Over 1500 patients have been enrolled in clinical trials of the vaccine. Phase I and II clinical trials have tested the vaccine in a number of cancer indications, including breast, ovarian, and colorectal cancers. The phase III trial involved 1030 women with metastatic breast cancer.
The company, and its collaborator Merck KGaA of Darmstadt, Germany, announced in June that the phase III trial of Theratope did not meet the two predetermined statistical endpoints of time to disease progression and overall survival. However, in one prestratified subset of over 300 women on hormonal treatment following chemotherapy, those on the Theratope arm appeared to show a favorable trend to improvement in survival. Further analyses of this subset are continuing ...
- MERCK KGAA STARTS PHASE III STUDY OF STIMUVAX IN BREAST CANCER.
- News wire article from: AsiaPulse News June 22, 2009 700+ words
...MERCK-KGAA) Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer Merck KGaA announces the launch...Stimuvax, in advanced breast cancer DARMSTADT, Germany...Jun. 22, 2009-- Merck KGaA, Darmstadt, Germany...
- Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer.
- Press release article from: Business Wire June 22, 2009 700+ words
...in advanced breast cancer DARMSTADT, Germany -- Merck KGaA, Darmstadt...sponsored by Merck KGaA, which is...with advanced breast cancer at an estimated...In aDvanced brEast cancer (b)START...was done by Merck KGaA. References...
- First patient enrolled in Theratope vaccine phase II trial.(Biomira Inc. and...
- Newspaper article from: Immunotherapy Weekly October 30, 2002 700+ words
...BIOM) and Merck KGaA announced that...with metastatic breast cancer who are being...with metastatic breast cancer. Approximately...these metastatic breast cancer patients. A...Biomira and Merck KGaA completed enrollment...
- Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer.(Report)
- Newspaper article from: Cancer Vaccine Week July 6, 2009 700+ words
...is sponsored by Merck KGaA, which is leading...Stimuvax (see also Merck KGaA). STRIDE will...with advanced breast cancer at an estimated...Unit Oncology, Merck KGaA. Keywords...AsiaBiotechnology, Breast Cancer, Breast Carcinoma...
- Biomira and Merck KGaA. (In the Pipeline).(Theratope breast cancer vaccine...
- Newspaper article from: Drug Utilization Review November 1, 2002 700+ words
Biomira and Merck KGaA have announced that investigators have enrolled the first patient in a Phase II trial of Theratope vaccine in women with metastatic breast cancer who are being treated with aromatase inhibitors or fulvestrant...
- BIOMIRA, MERCK KGAA MISS EARLY THERATOPE ENDPOINTS.(jointly investigating...
- Magazine article from: BIOWORLD Today Huggett, Brady September 20, 2002 700+ words
...result of Biomira Inc. and partner Merck KGaA ratcheting up the bar for Theratope...their Phase III trial in metastatic breast cancer was not an exalting triumph, but that...Theratope vaccine in women with metastatic breast cancer who are being treated with aromatase...
- Biomira Inc. (Active Pharmaceutical Ingredient Watch).(Biomira Inc and Merck...
- Magazine article from: Chemical Market Reporter June 30, 2003 700+ words
BIOMIRA Inc. and Merck KGaA report that vaccine Theratope has failed two predetermined end...and overall survival in a pivotal Phase III trial in metastatic breast cancer. Further analysis is underway of a subset of patients on hormonal...
- Biomira and Merck KGaA Announce Phase III Theratope(R) Vaccine Trial Does Not...
- Press release article from: PR Newswire June 17, 2003 700+ words
...TSX:BRA) and Merck KGaA of Darmstadt...with metastatic breast cancer did not meet the...III metastatic breast cancer study and determine...Pharmaceuticals Inc., Merck KGaA's wholly-owned...with metastatic breast cancer being treated with...disease. Biomira ...
